Chemistry:Dexanabinol
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H38O3 |
| Molar mass | 386.576 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Dexanabinol (HU-211 or ETS2101[1]) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210.[2] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead as an NMDA antagonist.[3] It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for applications such as treating head injury, stroke, or cancer.[4][5][6] It was shown to be safe in clinical trials[7] and is currently undergoing Phase I trials for the treatment of brain cancer[8] and advanced solid tumors.[9]
Clinical trials
Dexanabinol has been studied in IV administration and oral dosing.[10] e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers.[11] Phase II studies are planned based on the results of the current trials.
A phase 1b study for hepatocellular carcinoma and pancreatic cancer was started in 2015.[12]
Legal status
HU-211 is not listed in the schedules set out by the United Nations ' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[13] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-211.
United States
HU-211 is not listed in the list of scheduled controlled substances in the USA.[14] It is therefore not scheduled at the federal level in the United States , but it is possible that HU-211 could legally be considered an analog of Delta-8-THC (one of the THC isomers which is in Schedule I under the designation of "Tetrahydrocannabinols"), and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.[15]
HU-211 is a Schedule I controlled substance in Alabama.[16]
HU-211 is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[17]
Effective January 1, 2016, HU-211 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."[18]
See also
References
- ↑ "e-therapeutics Clinical Development Pipeline". http://www.etherapeutics.co.uk/index.php?option=com_content&view=article&id=3&Itemid=5.
- ↑ "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design 6 (13): 1347–60. September 2000. doi:10.2174/1381612003399446. PMID 10903397.
- ↑ "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America 86 (23): 9584–7. December 1989. doi:10.1073/pnas.86.23.9584. PMID 2556719. Bibcode: 1989PNAS...86.9584F.
- ↑ "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research 17 (4): 275–80. August 1995. doi:10.1080/01616412.1995.11740326. PMID 7477742.
- ↑ "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs 6 (10): 976–9. October 2003. PMID 14534855.
- ↑ "Multifunctional drugs for head injury". Neurotherapeutics 6 (1): 28–42. January 2009. doi:10.1016/j.nurt.2008.10.036. PMID 19110197.
- ↑ "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". The Lancet. Neurology 5 (1): 38–45. January 2006. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021.
- ↑ University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.
- ↑ A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours. NIH. January 26, 2015. https://clinicaltrials.gov/ct2/show/NCT01489826?term=Dexanabinol&rank=3.
- ↑ "e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies". 18 December 2014. http://etherapeutics.co.uk/userfiles/file/ETS2101_Phase_Ia_to_Phase_Ib_Final.pdf.
- ↑ "Clinical Development Pipeline". http://etherapeutics.co.uk/pipeline.html.
- ↑ "A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours - Full Text View - ClinicalTrials.gov". https://clinicaltrials.gov/ct2/show/NCT02423239?term=Dexanabinol&rank=1.
- ↑ "UN International Drug Control Conventions". https://www.unodc.org/unodc/en/commissions/CND/conventions.html.
- ↑ "§1308.11 Schedule I.". http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm.
- ↑ Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary
- ↑ "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd.". March 2014. https://legiscan.com/AL/text/SB333/2014.
- ↑ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
- ↑ Vermont DOH - Regulated Drug Rule 2016 .PDF
 |  |
